CDER Shifts Dispute Resolution Program Due to Spike in Appeals

International Pharmaceutical Regulatory Monitor
A A
An increased number of generic appeals has led CDER to transfer the management of its Formal Dispute Resolution program for sponsors of user fee products from the Office of New Drugs to the Office of Executive Programs, CDER Director Janet Woodcock said in a staff memo.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor